Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
Immuneering Corporation (IMRX) filed its Q3 2025 10-Q, highlighting a major balance sheet step-up driven by equity financings. Cash and cash equivalents were $227.6 million as of September 30, 2025, up from $36.1 million at year-end 2024, primarily from a $164.1 million underwritten offering, a $23.3 million private placement with Aventis (Sanofi), a $23.4 million August private placement including pre-funded and purchase warrants, and activity under its ATM program.
Operations remained consistent with development stage activity. Q3 2025 net loss was $15.0 million (loss per share $0.38), with R&D $10.9 million and G&A $4.5 million. For the nine months, the company reported a $44.4 million net loss. Management stated its cash is expected to fund operations for at least 12 months from issuance. The company continues advancing atebimetinib (IMM‑1‑104), including an ongoing Phase 1/2a and a planned registrational trial in first-line pancreatic cancer. Shares outstanding were 64,569,967 Class A as of November 5, 2025.
Immuneering Corporation announced its financial results for the quarter ended September 30, 2025 and shared operational updates. The details are contained in a press release dated November 12, 2025, which is provided as an exhibit and treated as furnished rather than filed under securities laws.
FMR LLC and Abigail P. Johnson reported beneficial ownership of 8,787,052 shares of Immuneering Corp Class A common stock, representing 14.5% of the class as of 09/30/2025. The filing shows FMR LLC holds 8,780,283 shares with sole voting power and 8,787,052 shares with sole dispositive power, while Abigail P. Johnson is reported with sole dispositive power for the same 8,787,052 shares.
The filing discloses that the Fidelity Growth Company Commingled Pool held 3,317,460 shares, or 5.5% of the class, at the same date. Signatures attest the holdings were acquired in the ordinary course of business and not for the purpose of changing control.
Insider purchase by Director Peter Feinberg. The filing shows a purchase of 7,500 shares of Class A common stock on 10/03/2025 at a reported price of $6.67 per share. After the transaction, Mr. Feinberg directly owns 156,766 shares and indirectly beneficially owns larger stakes through entities: 392,242, 476,615, and 115,441 shares via three general‑partner relationships, bringing total reported beneficial holdings across direct and indirect positions to a material position in the company.
HBM Healthcare Investments (Cayman) Ltd. filed a Schedule 13G reporting beneficial ownership of 3,646,304 shares of Immuneering Corp Class A common stock, representing approximately 5.7% of the 63,483,397 shares outstanding as of September 30, 2025. The filing states the shares were not acquired to change or influence control of the company and that voting and investment power is exercised by HBM's board.
The reporting person is organized in the Cayman Islands and lists sole voting and dispositive power over all reported shares. The statement includes a signature by Jean-Marc LeSieur, Managing Director, dated 10/03/2025.
Insider purchase reported: Immuneering Corp (IMRX) Chief Accounting Officer Mallory Morales reported acquiring 300 shares of Class A common stock on 10/01/2025 at a price of $6.39 per share. After the transaction, Morales beneficially owns 27,533 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. No derivative transactions or additional remarks were reported in the filing.
Insider transaction reported for Immuneering Corp (IMRX). Leah R. Neufeld, listed as Chief People Officer and reporting person, purchased 800 shares of Class A common stock on 10/01/2025 at a price of $6.3792 per share. After the purchase, the filing reports 23,344 shares beneficially owned. The Form 4 was signed on behalf of Ms. Neufeld by an attorney-in-fact and dated 10/02/2025.
Immuneering Corp (IMRX) Chief Legal Officer and Secretary Michael D. Bookman reported a personal purchase of 1,020 shares of Class A common stock on 10/01/2025 at a price of $6.8299 per share. Following the transaction, Mr. Bookman beneficially owns 4,870 shares. The Form 4 was signed on 10/02/2025 and lists his role as an officer and director. No derivative transactions or additional remarks were reported on the filing.
Insider purchase reported by Immuneering Corp (IMRX) Peter Feinberg, identified as a Director, reported purchasing 7,500 shares of Class A Common Stock on 09/30/2025 at a weighted-average price of $7.0307 per share. After the purchase Feinberg directly beneficially owned 149,266 shares and also reported indirect holdings of 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC. The filing notes the purchase was executed in multiple trades at prices from $7.0049 to $7.055. The Form 4 is signed by an attorney-in-fact on 10/01/2025.
Peter Feinberg, a director of Immuneering Corp (IMRX), reported a purchase of 5,000 Class A common shares on 09/29/2025 at a price of $7.18 per share. After the transaction he beneficially owns 141,766 shares directly, plus additional indirect holdings through entities (392,242; 476,615; 115,441), as listed on the Form 4. The filing was signed by an attorney-in-fact on 09/30/2025. This Form 4 discloses an insider purchase that increases the reporting person’s stake but contains no other financial metrics or commentary.